Clinical Trial Update: Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients [Phase 2, Phase 3]

View source ↗

Summary

Ongoing Phase 2/Phase 3 clinical trials are evaluating EB-1020 for efficacy and safety in adults with attention deficit hyperactivity disorder, with recruitment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• EB-1020

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2, Phase 3 | Status: RECRUITING